Advertisement

Topics

Bionomics Limited Company Profile

13:11 EDT 24th September 2018 | BioPortfolio

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule and antibody product development programs in the areas of cancer, anxiety, and memory loss. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.
BNC105, which is undergoing Phase II clinical development in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics’ pipeline and underpin its established business strategy of securing partners for its key compounds.

Pipeline

Bionomics has a portfolio of drug candidates with potentially significant end-user markets with unmet clinical needs. Bionomics' pipeline includes BNC105, a "best in class" vascular disrupting agent for the treatment of solid tumours which is currently in Phase II clinical trials; BNC210, under development for the treatment of anxiety disorders by Bionomics' partner Ironwood Pharmaceuticals; and Kv1.3 blockers for the treatment of Multiple Sclerosis and other autoimmune conditions in partnership with Merck Serono. The latest addition to the pipeline is the Alpha 7 program which targets conditions where memory is impaired, including Alzheimer's Disease.

Location

31 Dalgleish Street
Thebarton
SA
5031
Australia

Contact

Phone: +618 8354 6100
Fax: +618 8354 6199
Email: investorrelations@bionomics.com.au


News Articles [42 Associated News Articles listed on BioPortfolio]

Bionomics (BNO) - Phase IIa in agitation of the elderly initiated

Edison Investment Research - Pharmaceutical & healthcare - Bionomics: Bionomics announced on 23 May 2018 it has initiated a Phase IIa study of its α7 nicotinic receptor inhibitor for the treatme...

Deborah Rathjen explains why these are exciting times for Bionomics

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr Deborah Rathjen, CEO and MD of Bionomics Ltd.

Bionomics (BNO) - RESTORE trial completed, data this quarter

Edison Investment Research - Pharmaceutical & healthcare - Bionomics: Bionomics announced on 9 July 2018 that it had completed treatment in its 193-patient Phase II clinical study of BNC210 for post-t...

Bionomics (BNO) - PTSD programme on track for results in Q3

Edison Investment Research - Pharmaceutical & healthcare - Bionomics: The fiscal year 2018, which ended in June, was a major transition for Bionomics as it realigned itself to focus on disorders of th...

Bionomics (BNO) - Novel mechanisms in drug discovery

Edison Investment Research - Pharmaceutical & healthcare - Bionomics: We are re-initiating coverage on Bionomics, a pharmaceutical company developing drugs for neuropsychiatric indications and oncolog...

Bionomics Ltd: Deborah Rathjen shares their positive results from clinical trials in the areas of CNS and Oncology

In this episode of PharmaTelevision News Review, Fintan Walton talks to Deborah Rathjen, CEO and Managing Director of Bionomics Ltd.

Bionomics begins Phase II trial of BNC210 to treat agitation

Bionomics has started a Phase II clinical trial of BNC210 for treating agitation in elderly patients. The trial will be...Read More... The post Bionomics begins Phase II trial of BNC210 to treat agita...

Bionomics: Deborah Rathjen. Strategic partnering to ensure a well-balanced yet diverse pipeline in CNS and Oncology

In this episode of PharmaTelevision News Review, filmed at AusBio 2012 in Melbourne, Australia, Fintan Walton talks to Deborah Rathjen, CEO and MD at Bionomics

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

First Record of Aedes (Stegomyia) malayensis Colless (Diptera: Culicidae) in the Lao People's Democratic Republic, Based on Morphological Diagnosis and Molecular Analysis.

This is the first confirmed record of Aedes (Stegomyia) malayensis Colless from the Lao People's Democratic Republic. Its larvae were collected from rock pools and rock holes along the Nam Noy River i...

Bionomics of Anopheles subpictus (Diptera: Culicidae) in a Malaria Endemic Area, Southeastern Iran.

Anopheles subpictus Grassi is considered a secondary malaria vector in parts of Asia. The current study determined some ecological and bionomical characteristics of this species in southeastern Iran. ...

Influence of Rearing Substrates and Nontarget Hosts on the Bionomics of the Tachinid Parasitoid Nemorilla maculosa (Diptera: Tachinidae).

The tachinid Nemorilla maculosa Meigen (Diptera: Tachinidae) was introduced from Taiwan to Benin for evaluating its potential as a biocontrol candidate against the cowpea pest Maruca vitrata (Fabriciu...

Clinical Trials [0 Results]

None

Companies [85 Associated Companies listed on BioPortfolio]

Bionomics Limited

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Biono...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

Ironwood Pharmaceuticals, Inc. and Bionomics Limited

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC-C agonis...

More Information about "Bionomics Limited" on BioPortfolio

We have published hundreds of Bionomics Limited news stories on BioPortfolio along with dozens of Bionomics Limited Clinical Trials and PubMed Articles about Bionomics Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bionomics Limited Companies in our database. You can also find out about relevant Bionomics Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record